Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2018 Dec 6;13(12):e0209108. doi: 10.1371/journal.pone.0209108

Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow

Andrzej Lange, Emilia Jaskula, Janusz Lange, Grzegorz Dworacki, Dorota Nowak, Aleksandra Simiczyjew, Monika Mordak-Domagala, Mariola Sedzimirska
PMCID: PMC6283549  PMID: 30521628

The following information is missing from the Funding section: Publication of this study was supported by Wroclaw Centre of Biotechnology, programme The Leading National Research Centre (KNOW) for years 2014–2018.

Reference

  • 1.Lange A, Jaskula E, Lange J, Dworacki G, Nowak D, Simiczyjew A, et al. (2018) The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PLoS ONE 13(1): e0190525 10.1371/journal.pone.0190525 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES